PBAC's latest decision on Decitabine with cedazuridine: Recommended with restriction (2021). Considered for Treatment of myelodysplastic syndrome (MDS) classified as intermediate-2 or high-risk according to the International Prognostic Scoring System (IPSS) and chronic myelomonocytic leukaemia (CMML).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2021
Submissions
1
2021 → 2021
Eligible population
Adult patients with myelodysplastic syndrome (MDS) classified as intermediate-2 or high-risk according to the International Prognostic Scoring System (IPSS) or chronic myelomonocytic leukaemia (CMML).
Therapy area
Haematology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
azacitidine
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated. Economic evaluation based on cost-neutrality versus azacitidine with adjusted supply chain costs.
Risk sharing
Risk-sharing arrangement in place — Risk Sharing Arrangement with financial caps based on revised financial estimates and rebate for use exceeding caps; rebate percentage redacted.